Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a patient oriented translational research project aiming to improve clinical outcomes
for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic
melanoma who have progressed on, or are unable to receive standard therapy (in general,
immunotherapy). Consecutive patients seen at three major clinics and fitting the broad
eligibility criteria will be invited to participate.
The approach is designed to test the impact of different targeted drugs on different
mutations in a single type of cancer. In this project, patients will have tumour tissue
genetically profiled to determine which mutation(s) are present, and will then be assigned to
receive a matched drug expected to target the mutation(s) in the tumour. Where multiple
targets are identified in one patient, or where multiple potential therapies would be
appropriate for a single tumour mutation, the treating clinician may determine the
appropriate therapeutic approach after consultation with the study team, using the latest
version of library of matched therapies.